NovoCure Up 50% After Two-Year Survival Rate Increases For GBM Patients

Novocure Ltd NVCR shares are trading higher by $4.00 (47 percent) at $12.10 in Monday's session.

On Sunday night, the company announced the two-year survival rate for GBM patients increased from 30 percent to 43 percent for patients treated with Optune + Temozolomide versus Temozolomide Alone at AACR 2017.

After a much higher open, Novocure's stock continued in that direction before peaking at $14.30, over $6.00 higher than Friday's closing price of $8.10. That elevated level coincides with a pair of highs from April 25, 2016 ($14.42) and April 26 ($14.37).

Profit-takers have come into the stock and as of 10:38 a.m. ET, it has found intra-day support at $11.55 and is attempting to remain in the $12.00 handle.